140 related articles for article (PubMed ID: 22694288)
1. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
Daud A; Soon C; Dummer R; Eggermont AM; Hwu WJ; Grob JJ; Garbe C; Hauschild A
Expert Opin Biol Ther; 2012 Aug; 12(8):1087-99. PubMed ID: 22694288
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
Chiarion-Sileni V; Del Bianco P; Romanini A; Guida M; Paccagnella A; Dalla Palma M; Naglieri E; Ridolfi R; Silvestri B; Michiara M; De Salvo GL
BMC Cancer; 2006 Feb; 6():44. PubMed ID: 16504154
[TBL] [Abstract][Full Text] [Related]
3. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.
Trinh VA; Zobniw C; Hwu WJ
Expert Opin Drug Saf; 2017 Aug; 16(8):933-940. PubMed ID: 28627943
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
6. Sylatron: a pegylated interferon for use in melanoma.
Patel JN; Walko CM
Ann Pharmacother; 2012 Jun; 46(6):830-8. PubMed ID: 22619474
[TBL] [Abstract][Full Text] [Related]
7. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
Dummer R; Garbe C; Thompson JA; Eggermont AM; Yoo K; Maier T; Bergstrom B
J Clin Oncol; 2006 Mar; 24(7):1188-94. PubMed ID: 16505439
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.
Kirkwood JM; Bender C; Agarwala S; Tarhini A; Shipe-Spotloe J; Smelko B; Donnelly S; Stover L
J Clin Oncol; 2002 Sep; 20(17):3703-18. PubMed ID: 12202672
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.
Navid F; Herzog CE; Sandoval J; Daryani VM; Stewart CF; Gattuso J; Mandrell B; Phipps S; Chemaitilly W; Sykes A; Davidoff AM; Shulkin BL; Bahrami A; Furman WL; Mao S; Wu J; Schiff D; Rao B; Pappo A
Pediatr Blood Cancer; 2016 Jul; 63(7):1207-13. PubMed ID: 27038395
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy of cutaneous melanoma: the interferon debate.
Kefford RF
Ann Oncol; 2003 Mar; 14(3):358-65. PubMed ID: 12598338
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
Gogas H; Bafaloukos D; Ioannovich J; Skarlos D; Polyzos A; Fountzilas G; Kalofonos HP; Aravantinos G; Tsoutsos D; Panagiotou P; Frangia K; Petrakopoulou T; Pectasides D;
Anticancer Res; 2004; 24(3b):1947-52. PubMed ID: 15274382
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
15. U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.
Herndon TM; Demko SG; Jiang X; He K; Gootenberg JE; Cohen MH; Keegan P; Pazdur R
Oncologist; 2012; 17(10):1323-8. PubMed ID: 23002124
[TBL] [Abstract][Full Text] [Related]
16. [High-dose interferon alpha in treatment of patients with malignant melanoma, monitoring of predictive and prognostic biomarkers].
Vanásková J; Grim J; Kopecký J; Kubala E; Filip S
Klin Onkol; 2011; 24(3):180-6. PubMed ID: 21717787
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.
Ascierto PA; Gogas HJ; Grob JJ; Algarra SM; Mohr P; Hansson J; Hauschild A
Crit Rev Oncol Hematol; 2013 Feb; 85(2):149-61. PubMed ID: 22874771
[TBL] [Abstract][Full Text] [Related]
18. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
Agarwala SS
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alph-2b (Sylatron) for melanoma.
Med Lett Drugs Ther; 2011 Sep; 53(1373):76. PubMed ID: 21921873
[No Abstract] [Full Text] [Related]
20. Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective.
Rubin KM; Vona K; Madden K; McGettigan S; Braun IM
Support Care Cancer; 2012 Aug; 20(8):1601-11. PubMed ID: 22562583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
